-- 兩位美國參議員週五敦促商品期貨交易委員會(CFTC)調查他們所謂的在川普總統3月和4月兩次就中東衝突發表最新聲明前夕的原油期貨可疑交易。 兩位議員在致CFTC主席邁克爾·S·塞利格的信中表示,在2026年3月23日和4月7日兩次重要政策聲明發布前不久,出現了大量且時機恰當的押注,這可能表明存在濫用非公開政府信息的情況。 「這種模式引發了人們對是否存在反覆濫用重大非公開政府資訊以及政府內外人員在多大程度上利用此類資訊採取行動的嚴重質疑,」兩位議員在信中寫道。 信中指出,在川普宣布與伊朗達成為期兩週的停火協議前幾個小時,交易員在4月7日押注約9.5億美元押注油價下跌。該聲明導致油價暴跌約15%。 議員表示,就在川普宣布將舉行會談以緩和戰爭局勢之前,3月23日原油期貨交易量激增,此舉導致原油價格下跌,股市指數上漲。 信中指出,有報道稱,紐約商品交易所身份不明的交易員在川普宣布相關消息前幾分鐘進行了一筆5億美元的「石油押注」。 參議員表示:“在川普宣布相關消息之前,沒有任何公開消息可以解釋價格的波動。” 議員們也指出,市場活動呈現出更廣泛的模式,即預期政府將做出重大決定。 信中引述路透社的一項調查,指出其他涉及股票選擇權和預測市場的案例,交易員似乎也在政策宣布前獲利。 信中還提到,此前有報道稱,與2025年4月暫停加徵關稅的公告相關的收益,以及今年早些時候對委內瑞拉政治局勢發展和美國可能對伊朗採取軍事行動的押注。 參議員詢問美國商品期貨交易委員會(CFTC)執法部門是否已對3月和4月的石油交易展開調查,如果沒有,原因是什麼。議員們還要求提供該機構監控機制以及與交易所協調以發現異常交易模式的詳細資訊。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.
Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.
Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.